---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-123841"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T16:57:47.513834+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# iBio prices $4.5M public offering of common stock and warrants at $2.00/unit

## Summary
- Gross proceeds $4.5M; net proceeds ~$3.6M after fees and expenses.
- Offering comprises 2.25M shares (or pre-funded warrants) plus Series C (2-year) and Series D (5-year) warrants.
- Series C and D warrants each exercisable for one share at $2.00, immediately exercisable.
- Closing expected Dec 7, 2023; proceeds for working capital, R&D, and severance payments.
- A.G.P./Alliance Global Partners lead placement agent; Brookline Capital Markets co-placement agent.

## SEC filing metadata
- accession: 0001104659-23-123841
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465923123841/0001104659-23-123841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465923123841/tm2332212d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-123841
- JSON: https://secwatch.observer/filing/0001104659-23-123841.json
- Plain text: https://secwatch.observer/filing/0001104659-23-123841.txt

## Key facts
- Material Agreements
  iBio, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC valued at 5.5% of the gross proceeds (effective 2023-12-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC
  - Value: 5.5% of the gross proceeds
  - Effective: 2023-12-05
  source text: On December 5, 2023, the Company entered into a placement agency agreement (the “ Placement Agency Agreement ”) with A.G.P./Alliance Global Partners (“ A.G.P. ”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“ Brookline ”), as co-placement agent (A.G.P. and Brookline are referred to herein, collectively, as the “ Placement Agents ”), pursuant to which the Placement Agents agreed to serve as the placement agents for the Company on a “reasonable efforts basis” for the issuance and sale of the Shares and Warrants.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000110465923123841/0001104659-23-123841-index.htm
- Material Agreements
  iBio, Inc. entered into Purchase Agreement with certain purchaser (the "Purchasers") valued at approximately $3.6 million (effective 2023-12-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchaser (the "Purchasers")
  - Value: approximately $3.6 million
  - Effective: 2023-12-05
  source text: On December 5, 2023, iBio, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement with certain purchaser (the “ Purchasers ”) identified on the signature pages thereto (the “ Purchase Agreement ”), pursuant to which the Company agreed to issue and sell, in a public offering (the “ Offering ”), (i) 600,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) 1,650,000 pre-funded warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000110465923123841/0001104659-23-123841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.